Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Vericel Corporation (VCEL)

Vericel Corporation (VCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,788,727
  • Shares Outstanding, K 49,358
  • Annual Sales, $ 197,520 K
  • Annual Income, $ -3,180 K
  • EBIT $ -1 M
  • EBITDA $ 3 M
  • 60-Month Beta 1.71
  • Price/Sales 13.73
  • Price/Cash Flow 3,118.27
  • Price/Book 10.46

Options Overview Details

View History
  • Implied Volatility 59.65% ( -2.76%)
  • Historical Volatility 41.04%
  • IV Percentile 92%
  • IV Rank 56.96%
  • IV High 81.37% on 11/06/24
  • IV Low 30.91% on 12/27/23
  • Put/Call Vol Ratio 0.96
  • Today's Volume 1,021
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 2,657
  • Open Int (30-Day) 2,444

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.32
  • Number of Estimates 3
  • High Estimate 0.37
  • Low Estimate 0.26
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +23.08%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.17 +4.30%
on 12/19/24
61.49 -8.12%
on 11/25/24
-0.76 (-1.33%)
since 11/20/24
3-Month
39.12 +44.43%
on 10/10/24
61.49 -8.12%
on 11/25/24
+9.93 (+21.32%)
since 09/20/24
52-Week
32.31 +74.87%
on 01/08/24
61.49 -8.12%
on 11/25/24
+22.46 (+65.98%)
since 12/20/23

Most Recent Stories

More News
Vericel Reports Third Quarter 2024 Financial Results

VCEL : 56.50 (+2.82%)
Vericel to Report Third-Quarter 2024 Financial Results on November 7, 2024

VCEL : 56.50 (+2.82%)
Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor

/PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments...

SGTX : 22.47 (-2.56%)
ATRS : 5.59 (unch)
VCEL : 56.50 (+2.82%)
Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

Kytopen , an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to...

VCEL : 56.50 (+2.82%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 56.50 (+2.82%)
OCEL : 2.7500 (unch)
BRTX : 1.5500 (+6.90%)
MDXG : 9.10 (+0.22%)
NNVC : 1.4900 (+2.76%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

/PRNewswire/ -- Chronic obstructive pulmonary disease is a chronic lung disease that prevents airflow from the lungs. The rising incidence of COPD is one...

OCEL : 2.7500 (unch)
BRTX : 1.5500 (+6.90%)
MDXG : 9.10 (+0.22%)
NNVC : 1.4900 (+2.76%)
VCEL : 56.50 (+2.82%)
Vericel (VCEL) Q2 2022 Earnings Call Transcript

VCEL earnings call for the period ending June 30, 2022.

VCEL : 56.50 (+2.82%)
Vericel Reports Second Quarter 2022 Financial Results

Second Quarter Total Net Revenue of $37.0 Million MACI Net Revenue of $28.6 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE,...

VCEL : 56.50 (+2.82%)
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

Data published in the Journal of Burn Care & Research show 83% of patients with posterior burns (mean total body surface area of 56%) had successful...

VCEL : 56.50 (+2.82%)
Vericel (VCEL) Q1 2022 Earnings Call Transcript

VCEL earnings call for the period ending March 31, 2022.

VCEL : 56.50 (+2.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

3rd Resistance Point 60.61
2nd Resistance Point 58.91
1st Resistance Point 57.71
Last Price 56.50
1st Support Level 54.81
2nd Support Level 53.11
3rd Support Level 51.91

See More

52-Week High 61.49
Last Price 56.50
Fibonacci 61.8% 50.34
Fibonacci 50% 46.90
Fibonacci 38.2% 43.46
52-Week Low 32.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar